Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

• ClinicalTrials.gov Identifier: NCT03934372
• Recruitment Status: Recruiting
• First Posted: May 1, 2019
• Last Update Posted: October 30, 2020
• Sponsor: Incyte Biosciences International Sàrl
• Information provided by (Responsible Party): Incyte Corporation ( Incyte Biosciences International Sàrl )

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

Condition or disease	Intervention/treatment	Phase
Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphocytic Leukemia; Leukemia; Lymphoma; Solid Tumors	Drug: Ponatinib	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants
• Actual Study Start Date: January 29, 2020
• Estimated Primary Completion Date: October 31, 2021
• Estimated Study Completion Date: June 15, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ponatinib; Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.	Drug: Ponatinib; Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.; Other Name: Iclusig, INCB84344

Outcome Measures

Primary Outcome Measures :

1. Phase 1: Number of dose-limiting toxicities [ Time Frame: 28 days ]
   Defined as the occurrence of any protocol-defined toxicities occurring after dosing and up to and including Day 28, except those toxicities with a clear alternative explanation.
2. Phase 2: Efficacy of ponatinib assessed by major cytogenetic response (MCyR) in participants with chronic-phase chronic myeloid leukemia (CP-CML) [ Time Frame: 12 months ]
   Defined as complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) as assessed by conventional cytogenetics or fluorescence in situ hybridization (FISH).
3. Phase 2: Efficacy of ponatinib assessed by major hematologic response (MaHR) or major molecular response (MMR) in participants with BCR-ABL-positive leukemias [ Time Frame: 3 months ]
   Assessed by polymerase chain reaction (PCR).
4. Phase 2: Efficacy of ponatinib assessed by complete response (CR) in participants with leukemias other than BCR-ABL-positive leukemias to determine the efficacy of ponatinib [ Time Frame: 6 months ]
5. Phase 2: Efficacy of ponatinib assessed by incomplete complete response (iCR) in participants with leukemias other than BCR-ABL-positive leukemias [ Time Frame: 6 months ]
   Assessed by conventional cytogenetics, FISH, or PCR.
6. Phase 2: Efficacy of ponatinib assessed by CR in participants with lymphoma [ Time Frame: 6 months ]
   According to Lugano criteria based on computed tomography (CT) or magnetic resonance imaging (MRI) (or positron emission tomography [PET]).
7. Phase 2: Efficacy of ponatinib assessed by overall response rate in participants with solid tumors [ Time Frame: 6 months ]
   Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for central nervous system (CNS) tumors or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for other solid tumors based on CT or MRI (or PET).

Secondary Outcome Measures :

1. Phase 1: Number of treatment-emergent adverse events [ Time Frame: 6 months ]
2. Phase 1: Tmax of ponatinib [ Time Frame: 6 months ]
   Time to maximum concentration.
3. Phase 1: AUCss,0-24 of ponatinib [ Time Frame: 6 months ]
   Area under the steady-state plasma or serum concentration-time curve from Hour 0 to 24.
4. Phase 1: t½ of ponatinib [ Time Frame: 6 months ]
   Apparent terminal-phase disposition half-life.
5. Phase 1: CLss/F of ponatinib [ Time Frame: 6 months ]
   Apparent oral dose clearance at steady state.
6. Phase 1: Vz/F of ponatinib [ Time Frame: 6 months ]
   Apparent oral dose volume of distribution.
7. Phase 1: MCyR in participants with BCR-ABL-positive leukemias [ Time Frame: 3 months ]
   Defined as CCyR or PCyR as assessed by conventional cytogenetics or FISH.
8. Phase 1: MMR in participants with BCR-ABL-positive leukemias [ Time Frame: 3 months ]
   Assessed by quantitative PCR (q-PCR).
9. Phase 1 and Phase 2: Complete hematologic response (CHR) in participants with CP-CML [ Time Frame: 6 months ]
10. Phase 1 and Phase 2: CCyR in participants with CP-CML [ Time Frame: 12 months ]
11. Phase 1 and Phase 2: MMR in participants with CP-CML [ Time Frame: 12 months ]
12. Phase 1 and Phase 2: Time to response (TTR) in participants with CP-CML [ Time Frame: 6 months ]
    Defined as the interval from the date of the first dose of study treatment to first response.
13. Phase 1 and Phase 2: Duration of response (DOR) in participants with CP-CML [ Time Frame: 6 months ]
    Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met.
14. Phase 1 and Phase 2: Progression-free survival (PFS) in participants with CP-CML [ Time Frame: 6 months ]
    Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier.
15. Phase 1 and Phase 2: Overall survival (OS) in participants with CP-CML [ Time Frame: 6 months ]
    Defined as the interval from the date of the first dose of study treatment until death from any cause.
16. Phase 1: CR in participants with leukemias other than BCR-ABL-positive leukemia or CP-CML. [ Time Frame: 6 months ]
17. Phase 1: CRi in participants with leukemias other than BCR-ABL-positive leukemia or CP-CML [ Time Frame: 6 months ]
    Assessed by conventional cytogenetics, FISH, or q-PCR.
18. Phase 1: CR in participants with lymphoma [ Time Frame: 6 months ]
    According to Lugano criteria based on CT or MRI (or PET).
19. Phase 1: Overall response rate in participants with solid tumors [ Time Frame: 6 months ]
    Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET).
20. Phase 2: Anticancer activity of ponatinib assessed by MaHR or MMR in participants with BCR-ABL-positive leukemias (AP-CML, BP-CML or Ph+ALL) [ Time Frame: 3 months ]
21. Phase 2: Anticancer activity of ponatinib assessed by CR in participants with leukemias other than BCR-ABL-positive leukemias [ Time Frame: 6 months ]
22. Phase 2: Anticancer activity of ponatinib assessed by CRi in participants with leukemias other than BCR-ABL-positive leukemias. [ Time Frame: 6 months ]
    Assessed by conventional cytogenetics, FISH, or PCR.
23. Phase 2: Anticancer activity of ponatinib assessed by CR in participants with lymphoma [ Time Frame: 6 months ]
    According to Lugano criteria based on CT or MRI (or PET).
24. Phase 2: Anticancer activity of ponatinib assessed by overall response rate in participants with solid tumors [ Time Frame: 6 months ]
    Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET).
25. Phase 2: OS in participants with solid tumors [ Time Frame: 6 months ]
    Defined as the interval from the date of the first dose of study treatment until death from any cause.
26. Phase 2: DOR in participants with solid tumors [ Time Frame: 6 months ]
    Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met.
27. Phase 2: PFS in participants with solid tumors [ Time Frame: 6 months ]
    Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier.
28. Phase 2: Number of treatment-emergent adverse events [ Time Frame: 6 months ]
29. Phase 2: Clearance of pediatric-friendly formulation of ponatinib [ Time Frame: 6 months ]
30. Phase 2: Volume of distribution of pediatric-friendly formulation of ponatinib [ Time Frame: 6 months ]
31. Phase 2: AUC of pediatric-friendly formulation of ponatinib [ Time Frame: 6 months ]

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of the following malignancies: CP-CML, blast phase chronic myeloid leukemia (BP-CML), accelerated phase chronic myeloid leukemia (AP-CML); acute lymphoblastic leukemia/acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); other leukemias; lymphoma; any other tumors, including tumors of the central nervous system (CNS), for which standard therapy is not available or is not indicated

• Phase 1:

  • Participants with CML who are resistant to or intolerant to at least 1 prior BCR-ABL-targeted TKI therapy.
  • Participants with ALL who have failed all available or indicated therapies, which may have included 1 prior BCR-ABL-targeted TKI therapy.
  • Participants with AML or other leukemias who have failed at least 1 prior induction attempt or for whom no effective standard therapy is available or indicated.
  • Participants with solid tumors (including tumors of the CNS) or lymphomas who have progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
• Phase 2 (CP-CML): Participants who are resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy or have the T315I kinase domain mutation.

• Phase 2 (other leukemias or solid tumors):

  • Participants with ALL who have failed all available or indicated therapies, which must have included 1 prior BCR-ABL-targeted TKI therapy.
  • Participants with AML or other leukemias who have failed at least 1 prior induction attempt or for whom no effective standard therapy is available or indicated.
  • Participants with solid tumors (including tumors of the CNS) with mutation of RET, KIT, FGFR, PDGFR, VEGFR or any other mutations where ponatinib may have biological activity or lymphomas who progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
• Karnofsky performance status ≥ 40% for participants > 16 years old or Lansky Play Scale ≥ 40 for pediatric participants ≤ 16 years old.
• Must have recovered to < Grade 2 per the NCI CTCAE v5.0 or to baseline from any non-hematologic toxicities (except alopecia) due to previous therapy.
• Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

• Participants with CP-CML who are in MCyR or better.

• Prior therapies:

  • Participants with BP-CML, ALL, or AML who have received corticosteroids or hydroxyurea within 24 hours before the first dose of ponatinib; vincristine within 7 days before the first dose of ponatinib; or other chemotherapy (excluding intrathecal chemotherapy) within 14 days before the first dose of ponatinib
  • Participants (except the BP-CML, ALL, and AML participants described above) who have had cytotoxic chemotherapy or radiotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) before the first dose of ponatinib.
  • Prior radiation therapy within 6 weeks or radio-isotope therapy within 6 weeks before the first dose of ponatinib.
  • Autologous or allogeneic stem cell transplant < 3 months before the first dose of ponatinib.
  • Prior treatment with any of the following: immunosuppressive therapy (including post stem cell transplant regimens) within 14 days before the first dose of ponatinib; any targeted cancer therapy (including TKIs) within 7 days before the first dose of ponatinib; any other investigational anticancer agents within 30 days or 5 half-lives, whichever is longer, before randomization; any monoclonal antibody-directed anticancer therapy within 5 half-lives of the first dose of ponatinib; any chimeric antigen receptor therapy within 28 days before the first dose of ponatinib; ponatinib.
• Laboratory values at screening outside the protocol-defined ranges.
• Significant concurrent, uncontrolled medical condition, including but not limited to protocol-defined pancreatic, cardiac, cerebral, coagulation, gastrointestinal, and genetic conditions.
• Any active ≥ Grade 2 graft-versus-host disease.
• Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.
• Known HIV infection.
• Known hypersensitivity or severe reaction to ponatinib or excipients of ponatinib.
• Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.
• Females who are pregnant or lactating.

Contacts and Locations

Contacts

Contact: Incyte Corporation Call Center (ex-US); +800 00027423; globalmedinfo@incyte.com

Locations

Belgium

Ghent University Hospital; Recruiting

Ghent, Belgium, 09000

Denmark

The Finsen Centre, National Hospital; Not yet recruiting

Copenhagen, Denmark, 02100

France

Hopital Robert Debre; Recruiting

Paris, France, 75019

Centre Hospitalier Universitaire de Poitiers; Recruiting

Poitiers, France, 86021

Italy

Fondazione Irccs Istituto Nazionale Dei Tumori; Recruiting

Milano, Italy, 20133

University of Milano Bicocca; Recruiting

Monza, Italy, 20900

Ospedale Pediatrico Bambino Gesu Irccs; Recruiting

Roma, Italy, 00165

Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza; Recruiting

Torino, Italy, 10126

Netherlands

Princess Maxima Center For Pediatric Oncology; Recruiting

Utrecht, Netherlands, 03584

Spain

Hospital Ni?O Jesus; Recruiting

Madrid, Spain, 28009

Hospital Universitario de La Paz; Recruiting

Madrid, Spain, 28046

Sweden

Karolinska Universitetssjukhuset Solna; Not yet recruiting

Solna, Sweden, 171 76

Karolinska University Hospital Huddinge; Recruiting

Stockholm, Sweden, 14141

United Kingdom

The Royal Marsden Nhs Foundation Trust - Sutton; Recruiting

Sutton, United Kingdom, SM2 5PT

The Royal Marsden NHS Foundation Trust; Not yet recruiting

Sutton, United Kingdom, SW3 6JJ

Sponsors and Collaborators

Incyte Biosciences International Sàrl

Investigators

• Study Director: Mohammed-El-Amine Bensmaine, MD; Incyte Biosciences International Sàrl

More Information

• Responsible Party: Incyte Biosciences International Sàrl
• ClinicalTrials.gov Identifier: NCT03934372
• Other Study ID Numbers: INCB 84344-102
• First Posted: May 1, 2019
• Last Update Posted: October 30, 2020
• Last Verified: October 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Incyte Corporation ( Incyte Biosciences International Sàrl ):

Leukemia; Solid tumors; Pediatric; Tyrosine kinase inhibitor

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Accelerated Phase; Leukemia, Lymphoid; Ponatinib; Blast Crisis; Neoplasms; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Cell Transformation, Neoplastic; Carcinogenesis; Neoplastic Processes; Pathologic Processes; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action